---
title: 'Merck, Sanofi, J&J, ThermoFisher, Novo Nordisk, Eli Lilly'
type: 'episode'
url: 'https://doc.social/episodes/merck-sanofi-jj-thermofisher-novo-nordisk-eli-lilly'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-05-03'
audio: 'unavailable — the host retired the file'
---

# Merck, Sanofi, J&J, ThermoFisher, Novo Nordisk, Eli Lilly

Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle loomsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesMerckSanofiJ&JThermoFisherNovo NordiskEli LillyAbout the ShowLife Science T…

## Summary

Pharma Q1 reports are rolling in, COVID boost turned sustainable, and weight loss battle looms

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References
**[Merck](https://www.merck.com/news/merck-announces-first-quarter-2022-financial-results/)
[Sanofi
](https://www.sanofi.com/en/media-room/press-releases/2022/2022-04-28-07-30-00-2430908)[J&J
](https://johnsonandjohnson.gcs-web.com/static-files/f1e185dd-938c-49b5-a409-9f54e553e5c8)[ThermoFisher](https://corporate.thermofisher.com/content/tfcorpsite/us/en/index/newsroom/press-releases/2022/Apr/28-Thermo-Fisher-Scientific-Reports-First-Quarter-2022-Results.html)
[Novo Nordisk
](https://www.pharmaceutical-technology.com/comment/novo-nordisks-wegovy-supply-challenges/)[Eli Lilly**
**](https://www.fiercebiotech.com/biotech/surmount-able-lillys-tirzepatide-clears-high-bar-set-novos-wegovy-obesity)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.